SMARCA4 and neoplasm: Moreover, once-daily treatment with CP-C27 led to marked suppression of tumor growth in SMARCA4/SMARCA2-deficient DMS114 and SS18–SSX fusion Fuji xenograft models (Fig. 6A–D), again with no adverse effect on the body weight of mice (Fig. 6E and F).